{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:46:55Z","timestamp":1787802415365,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the 2016 Chugoku Occupational Health Association Grant."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00432-021-03893-z","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T17:04:07Z","timestamp":1649264647000},"page":"1869-1877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study"],"prefix":"10.1007","volume":"148","author":[{"given":"Kenichiro","family":"Kudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kodani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagio","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Fujitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kanaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Itano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-0843","authenticated-orcid":false,"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"3893_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","volume":"11","author":"DR Camidge","year":"2014","unstructured":"Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11:473\u2013481. https:\/\/doi.org\/10.1038\/nrclinonc.2014.104","journal-title":"Nat Rev Clin Oncol"},{"key":"3893_CR2","doi-asserted-by":"publisher","first-page":"11815","DOI":"10.1038\/ncomms11815","volume":"7","author":"JJ Chabon","year":"2016","unstructured":"Chabon JJ, Simmons AD et al (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815. https:\/\/doi.org\/10.1038\/ncomms11815","journal-title":"Nat Commun"},{"key":"3893_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1586\/14737140.2013.845092","volume":"13","author":"R Costanzo","year":"2013","unstructured":"Costanzo R, Montanino A, Di Maio M et al (2013) Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Rev Anticancer Ther 13:1207\u20131218. https:\/\/doi.org\/10.1586\/14737140.2013.845092","journal-title":"Expert Rev Anticancer Ther"},{"key":"3893_CR4","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","volume":"10","author":"A Hata","year":"2015","unstructured":"Hata A, Katakami N, Yoshioka H et al (2015) Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 10:1553\u20131559. https:\/\/doi.org\/10.1097\/JTO.0000000000000647","journal-title":"J Thorac Oncol"},{"key":"3893_CR5","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2217\/fon-2019-0346","volume":"15","author":"MJ Hochmair","year":"2020","unstructured":"Hochmair MJ, Morabito A, Hao D et al (2020) Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol 15:2905\u20132914. https:\/\/doi.org\/10.2217\/fon-2019-0346","journal-title":"Future Oncol"},{"key":"3893_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S et al (2020) Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38:115\u2013123. https:\/\/doi.org\/10.1200\/JCO.19.01488","journal-title":"J Clin Oncol"},{"key":"3893_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10147-018-1344-x","volume":"24","author":"K Hotta","year":"2019","unstructured":"Hotta K, Ninomiya K, Ichihara E et al (2019) Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. Int J Clin Oncol 24:41\u201345. https:\/\/doi.org\/10.1007\/s10147-018-1344-x","journal-title":"Int J Clin Oncol"},{"key":"3893_CR8","doi-asserted-by":"publisher","first-page":"29525","DOI":"10.18632\/oncotarget.25705","volume":"9","author":"E Ichihara","year":"2018","unstructured":"Ichihara E, Hotta K, Kubo T et al (2018) Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget 9:29525\u201329531. https:\/\/doi.org\/10.18632\/oncotarget.25705","journal-title":"Oncotarget"},{"key":"3893_CR9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA J\u00e4nne","year":"2015","unstructured":"J\u00e4nne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689\u20131699. https:\/\/doi.org\/10.1056\/NEJMoa1411817","journal-title":"N Engl J Med"},{"key":"3893_CR10","unstructured":"JLCS (2019) Proceedings of the Japan Lung Cancer Society 2019. Presidential symposium (PS)-1, Osimertinib as first-line therapy for EGFRm advanced NSCLC (FLAURA): final OS in Japanese subset. http:\/\/journal.kyorin.co.jp\/journal\/haigan-am\/results_j.php?-DB=haigan_am&-action=find&-skip=0&-max=20&category_code=2019apdsy. Accessed 24 Oct 2021"},{"key":"3893_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00280-014-2425-9","volume":"73","author":"Y Kato","year":"2014","unstructured":"Kato Y, Hotta K, Takigawa N et al (2014) Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 73:943\u2013950. https:\/\/doi.org\/10.1007\/s00280-014-2425-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"3893_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00280-015-2910-9","volume":"77","author":"K Kudo","year":"2016","unstructured":"Kudo K, Hotta K, Bessho A et al (2016) Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 77:1005\u20131009. https:\/\/doi.org\/10.1007\/s00280-015-2910-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"3893_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/1878-0261.12063","volume":"11","author":"K Kudo","year":"2017","unstructured":"Kudo K, Ohashi K, Makimoto G et al (2017) Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. Mol Oncol 11:670\u2013681. https:\/\/doi.org\/10.1002\/1878-0261.12063","journal-title":"Mol Oncol"},{"key":"3893_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.02.006","volume":"65","author":"SM Lim","year":"2018","unstructured":"Lim SM, Syn NL, Cho BC et al (2018) Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev 65:1\u201310. https:\/\/doi.org\/10.1016\/j.ctrv.2018.02.006","journal-title":"Cancer Treat Rev"},{"key":"3893_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fonc.2014.00244","volume":"4","author":"B Melosky","year":"2014","unstructured":"Melosky B (2014) Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol 4:244. https:\/\/doi.org\/10.3389\/fonc.2014.00244","journal-title":"Front Oncol"},{"key":"3893_CR16","unstructured":"NCCN Guidelines (2021) NCCN guidelines version 2.2021 Non-small cell lung cancer. https:\/\/www.nccn.org\/ Accessed 1 July 2021"},{"key":"3893_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/1759-7714.13822","volume":"12","author":"T Ninomaru","year":"2021","unstructured":"Ninomaru T, Hata A, Kokan C et al (2021) Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first\/second generation EGFR-TKIs. Thorac Cancer 12:746\u2013751. https:\/\/doi.org\/10.1111\/1759-7714.13822","journal-title":"Thorac Cancer"},{"key":"3893_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100107","author":"K Ninomiya","year":"2021","unstructured":"Ninomiya K, Teraoka S, Zenke Y et al (2021) Japanese lung cancer society guidelines for Stage IV NSCLC with EGFR mutations. JTO Clin Res Rep. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100107","journal-title":"JTO Clin Res Rep"},{"key":"3893_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/1759-7714.13789","volume":"12","author":"K Nishii","year":"2021","unstructured":"Nishii K, Inoue M, Obata H et al (2021) Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol. Thorac Cancer 12:725\u2013731. https:\/\/doi.org\/10.1111\/1759-7714.13789","journal-title":"Thorac Cancer"},{"key":"3893_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00280-016-3146-z","volume":"78","author":"N Oda","year":"2016","unstructured":"Oda N, Hotta K, Yoshioka H et al (2016) Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 78:941\u2013947. https:\/\/doi.org\/10.1007\/s00280-016-3146-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"3893_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00280-018-3694-5","volume":"82","author":"N Oda","year":"2018","unstructured":"Oda N, Hotta K, Ninomiya K et al (2018) A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemother Pharmacol 82:1031\u20131038. https:\/\/doi.org\/10.1007\/s00280-018-3694-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"3893_CR22","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","volume":"31","author":"VA Papadimitrakopoulou","year":"2020","unstructured":"Papadimitrakopoulou VA, Mok TS, Han JY et al (2020) Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol 31:1536\u20131544. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2100","journal-title":"Ann Oncol"},{"key":"3893_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"3893_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.bbrc.2017.10.175","volume":"495","author":"T Tamura","year":"2018","unstructured":"Tamura T, Kato Y, Ohashi K et al (2018) Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochem Biophys Res Commun 495:360\u2013367. https:\/\/doi.org\/10.1016\/j.bbrc.2017.10.175","journal-title":"Biochem Biophys Res Commun"},{"issue":"suppl_1","key":"3893_CR25","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC et al (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29(suppl_1):i10\u2013i19. https:\/\/doi.org\/10.1093\/annonc\/mdx703","journal-title":"Ann Oncol"},{"key":"3893_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-0033-1342952","volume":"30","author":"RS Winokur","year":"2013","unstructured":"Winokur RS, Pua BB, Sullivan BW, Madoff DC (2013) Percutaneous lung biopsy: technique, efficacy, and complications. Semin Interv Radiol 30:121\u2013127. https:\/\/doi.org\/10.1055\/s-0033-1342952","journal-title":"Semin Interv Radiol"},{"key":"3893_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/JTO.0b013e31818020eb","volume":"3","author":"DR Youlden","year":"2008","unstructured":"Youlden DR, Cramb SM, Baade PD (2008) The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 3:819\u2013831. https:\/\/doi.org\/10.1097\/JTO.0b013e31818020eb","journal-title":"J Thorac Oncol"},{"key":"3893_CR28","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1158\/1078-0432.CCR-13-2437","volume":"20","author":"HA Yu","year":"2014","unstructured":"Yu HA, Riely GJ, Lovly CM (2014) Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 20:5898\u20135907. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2437","journal-title":"Clin Cancer Res"},{"key":"3893_CR29","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7:78985\u201378993. https:\/\/doi.org\/10.18632\/oncotarget.12587","journal-title":"Oncotarget"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03893-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03893-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03893-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T04:04:46Z","timestamp":1658117086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03893-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3893"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03893-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"23 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EI received honoraria from AstraZeneca, Eli Lilly Japan, Boehringer Ingelheim, and Chugai Pharmaceutical. EI received additional research funding from Eli Lilly Japan and the MSD. Dr. Hotta reports personal fees from Pfizer, grants and personal fees from AstraZeneca, grants and personal fees from Chugai, grants and personal fees from Lilly, personal fees from Takeda, grants and personal fees from MSD, grants and personal fees from BMS, personal fees from Ono, personal fees from Nippon Kayaku, personal fees from Taiho, personal fees from Boehringer, outside the submitted work. Dr. Takigawa reports personal fees from AstraZeneca, grants and personal fees from Daiichi Sankyo Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Pfizer, grants and personal fees from Boehringer Ingelheim, personal fees from Ono Pharmaceutical, personal fees from MSD, grants and personal fees from Eli Lilly, grants from Kyowa Hakko Kirin, grants from Nippon Kayaku, personal fees from Eisai, personal fees from Bristol-Myers Squibb, outside the submitted work. TM received honoraria from Takeda Pharmaceutical, Kyowa Hakko Kirin, Chugai Pharmaceutical, Novartis Pharmaceutical, Otsuka Pharmaceutical, Astellas Pharmaceutical, AsahiKASEI, Sumitomo Dainippon Pharmaceutical, Mochida Pharmaceutical, Bristol\u2013Myers Squibb, Pfizer, Nippon Shinyaku, Janssen Pharmaceutical, Celgene, Eisai, Mundipharma, and Meiji Seika Pharma. TM also received research funding from Akeda Pharmaceutical and Kyowa Hakko Kirin. KO received research grants from Boehringer Ingelheim and Novartis Pharmaceuticals, Japan. KK received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi Sankyo Pharmaceuticals, Chugai Pharmaceuticals, Taiho Pharmaceuticals, Boehringer Ingelheim, and Sanofi Aventis. All remaining authors declare no conflict of interest regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics committee of all affiliated hospitals approved the study protocol (No. 1703-055; Institutional Review Board of Okayama University Hospital).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors have consented to the submission of this original article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}